Multiple Sclerosis
Conference Coverage
Fingolimod Reduces Annualized Relapse Rate in Pediatric MS
PARIS—Among children and adolescents with multiple sclerosis (MS), patients treated with fingolimod have a lower annualized relapse rate, compared...
Conference Coverage
Oligoclonal Bands Could Be a Valuable Criterion for the Diagnosis of MS
PARIS—Oligoclonal bands, together with symptomatic lesions disseminated in space, increase the risk of multiple sclerosis (MS), according to data...
Conference Coverage
Does Concussion Increase the Risk of MS?
PARIS—Head trauma in adolescence, particularly if it is repeated, is associated with an increased risk of subsequent multiple sclerosis (MS),...
Conference Coverage
What Is the Prevalence of Truly Benign MS?
PARIS—Benign multiple sclerosis (MS) appears to be rare. Its estimated prevalence is less than 4%, according to a study described at the Seventh...
Conference Coverage
Interferon Beta May Reduce Mortality in MS
PARIS—Interferon beta is associated with a lower risk of all-cause mortality among patients with multiple sclerosis (MS) treated in clinical...
Conference Coverage
Siponimod Improves MRI Outcomes in Patients With Secondary Progressive MS
PARIS—Siponimod significantly reduces MRI activity and slows brain volume loss in patients with secondary progressive multiple sclerosis (MS),...
Medical Education Library
Highlights From the 7th Joint ECTRIMS‑ACTRIMS Meeting
Neurology Reviews presents selected news highlights from the 7th Joint ECTRIMS‑ACTRIMS Meeting.
Conference Coverage
MS Treatment Decisions Based on Milestones That Matter
PARIS—Tracking disease impact in patients with multiple sclerosis (MS) by predictable loss of economically important milestones...
Conference Coverage
Durable Improvements in Clinical Outcomes With Alemtuzumab: Seven-Year Follow-Up
PARIS—Clinical efficacy of alemtuzumab was maintained for seven years in patients who had inadequate response to prior therapy,...
Literature Review
How Does Cladribine Compare With Other MS Therapies?
New data confirm cladribine’s efficacy as a treatment for relapsing-remitting multiple sclerosis (MS), according to results published online ahead...
Conference Coverage
The Expanded Timed Get Up and Go Test Predicts MS Disability
PARIS—The Expanded Timed Get Up and Go (ETGUG) may be a more sensitive predictor of disability in multiple sclerosis (MS) than...